Camsirubicin received orphan designation in the EU for soft tissue sarcoma

Camsirubicin is a proprietary doxorubicin analog that is selective for topoisomerase-IIa. It has been investigated in advanced soft tissue sarcoma patients in a Phase 1 and a single arm Phase 2 clinical trial.

Biospace Inc.